RxDoctor Payments Data

Oscar Mendez, MD

Neurology · Franklin, TNNPI 1366403230

Payments from drug & device makers

$1,046in general payments, 2019–2025

Across 32 payments — averaging $32.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$213
  • Livanova USA, Inc.$143
  • Boston Scientific$138
  • Inspire Medical Systems, Inc.$133
  • Jazz Pharmaceuticals Inc.$100
  • Neurocrine Biosciences, Inc.$82
  • plus $236 from 9 others

What the payments were for

  • Food & beverage$88785%
  • Education$15915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,046 in reported general payments places this provider in the 35th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$119,039
Medicare patients
672
Services billed
998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate22$193,848
NuplazidPimavanserin Tartrate27$173,609
Memantine Hcl ErMemantine Hcl312$37,817
Emgality PenGalcanezumab-Gnlm23$23,135
NeuproRotigotine23$20,655
Nurtec OdtRimegepant Sulfate14$15,332
QuliptaAtogepant13$13,944
Carbidopa-LevodopaCarbidopa/Levodopa371$13,441
UbrelvyUbrogepant11$12,626
Memantine Hcl404$12,022
Gabapentin573$8,566
Aimovig AutoinjectorErenumab-Aooe11$8,393
Rivastigmine58$7,484
DepakoteDivalproex Sodium12$5,220
Pregabalin130$5,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$82$193,84822 claims
AbbVieQulipta, Ubrelvy$213$26,57124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 361 neurology providers in Tennessee.

Other neurology in Franklin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →